Skip to main content

Table 4 Relation of ABCB1 genotype and C/D ratio, tacrolimus dose, and trough levels among the recipient group 2 months and 3 months post transplantation (Mann–Whitney test)

From: Clinical utility of ABCB1 single nucleotide polymorphism on tacrolimus dose requirements in Egyptian liver transplant patients

ABCB1 CC CT+TT Z P-value Sig.
2nd month      
Dose Median (IQR) 0.1 (0.07–0.1) 0.05(0.03–0.08) −1.902 0.050 S
Range 0.04–0.1 0.02–0.1
Trough level Median (IQR) 5.3(3.8–10.6) 6.65(6.05–7.8) −0.797 0.426 NS
Range 2.9–12.9 2.2–14.6
C/D Median (IQR) 63.5(49–106) 126.5(88.25–207.5) −2.154 0.031 S
Range 47–143 55–486
3rd month      
Dose Median (IQR) 0.08(0.05–0.09) 0.05(0.03–0.07) −1.508 0.132 NS
Range 0.02–0.1 0.01–0.1
Trough level Median (IQR) 4.95(4.5–7.4) 5.8(3.3–7) −0.188 0.851 NS
Range 3.2–8.8 1.4–9.1
C/D Median (IQR) 76.5(61–176) 122(84.5–147.5) −0.469 0.639 NS
Range 32–225 47–205
  1. P-value >0.05, non-significant (NS); P-value <0.05, significant (S); P-value< 0.01, highly significant (HS)